

February 7-8, 2023

ANTI-BIOFILM TECHNOLOGIES:
Pathways to Product Development

Hilton Arlington National Landing Hotel, Arlington, VA

Draft AGENDA

11/29/2022 8:50 AM

**Tuesday
February 7**

7:30–8:00
Registration & Coffee
Commonwealth Foyer

Meeting: Richmond/Roanoke

8:00–8:15
Opening Remarks
Matthew Fields
Director, CBE; Professor,
Microbiology & Cell
Biology, MSU
Paul Sturman, Industrial
Coordinator, CBE

Keynote Presentation

8:15–9:00
**OSEL Sterility and Infection
Control Regulatory Science
Program: A focus on
stakeholder needs**
Michael Eppihimer, Director,
Division of Biology,
Chemistry and Material
Sciences, OSEL, CDRH,
US FDA

**SESSION 1: Reusable
Medical Devices**

9:00–9:30
**Effect of protein
concentration of biofilm
formation in
polytetrafluoroethylene
tubing**
Garth James, PI, Medical
Biofilms Laboratory, CBE;
Associate Research
Professor, Chemical &
Biological Engineering,
MSU

9:30–10:00
**Biofilm cleaning
performance evaluation in
Automated Endoscope
Reprocessors**
Bruno Haas, Group Leader,
Scientific, Research and
Validation Team, STERIS

10:00–10:30 Break

10:30–11:00
**Current state of flexible
endoscope reprocessing:
Why is build-up biofilm a
concern?**
Michelle Alfa, President,
AlfaMed Consulting, Ltd.

11:00–11:30
**Analyzing biofilm reduction
for cleaning of medical
device surfaces**
Jon Weeks, Research
Microbiologist, OSEL,
CDRH, US FDA

Panel Discussion
11:30–12:30
**Assessing cleaning
procedures for reusable
medical devices to improve
patient safety**

Michelle Alfa
Bruno Haas
Garth James
Jon Weeks
Moderator: Darla Goeres, CBE

12:30–1:30 Lunch Will/York

**SESSION 2:
Bioremediation**

1:30–2:10
**Session Introduction &
Presentation (title tba)**
Brent Peyton, Professor,
Chemical & Biological
Engineering, MSU, CBE

2:10–2:40
**Pharmaceutical effects on
aerobic granular sludge:
Treatment capacity,
morphology, and
communities**
Kylie Bodle, PhD Student,
Civil Eng., MSU, CBE

2:40–3:10 Break

3:10–3:40
Title TBA
Jim Cummings, US EPA

3:40–4:10
**Biofilm considerations:
Bioremediation of
contaminated groundwater**
Birthe Venø Kjellerup,
Associate Professor, Civil &
Environmental Eng.,
University of Maryland at
College Park

**Networking Reception
immediately following
meeting** Crystal Ballroom

**Wednesday
February 8**

8:00–8:20
Registration & Coffee
Commonwealth Foyer

**SESSION 3: Emerging
Surface Disinfection
Methods**

8:20–8:30
Session Introduction
Al Parker, Biostatistician,
CBE; Associate Research
Professor, Mathematical
Sciences, MSU

8:30–9:00

An overview of EPA's guidance and methods for adding residual efficacy claims

Rebecca Pines, Branch Chief,
Microbiology Laboratory
Branch, Office of Pesticide
Programs, US EPA

9:00–9:30

Multiple multi-lab evaluations of the Quantitative Method for determining the efficacy of antimicrobial substances against bacteria dried onto hard non-porous surfaces

Al Parker

9:30–10:00

Industry perspectives on the Quantitative Method to measure disinfection efficacy; progress to improve reproducibility and parameters for assessing suitability as a regulatory standard

John Hilgren, Director,
Regulatory Affairs, Ecolab

10:00–10:30 Break

10:30–11:00

New method for *Legionella pneumophila* claims in cooling tower water

Lisa Smith, Team Leader,
Microbiology Laboratory
Branch, Office of Pesticide
Programs, US EPA

11:00–11:30

Title TBA

Anastasia Swearingen,
Senior Director, Chemical
Products and Technology,
American Chemistry
Council

11:30–12:00

Good Riddance—The importance of biofilm removal and the need for standardized methods

Bruce Urtz, Microbiology
Manager, Sterilex

12:00–1:00 Lunch Will/York

SESSION 4: Global Perspectives on Biofilm Claims

1:00–1:10

Session Introduction

Darla Goeres, Research
Professor of Regulatory
Science, CBE

1:10–1:40

Antibiofilm surfaces in the built environment: Current methods and considerations for method development

James Redfern, Lecturer,
Natural Sciences,
Manchester Metro
University

1:40–2:10

Prevention and treatment of biofilms—Update on European method development and claims

Florian Brill, Managing
Director, Dr. Brill +
Partner, GmbH

2:10–2:40

The UK's standpoint on biofilm claims and methods in the medical devices sector

Paulina Rakowska,
Research
and Innovation
Development Manager,
National Biofilms
Innovation Centre
(NBIC)

2:40–3:20

Title TBA

Michel Birnbaum, Director,
Entrepreneurship and
Research Translation,
Singapore Centre for
Environmental Life
Sciences Engineering
(SCELSE)

